Program
roxadustat
Also written as “Roxadustat”, “FG-4592” and “ASP1517”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 221 open or running | phase 3since Jun 25, 2013 | Sep 15, 2009 | Oct 30, 2027phase 3 · NCT05970172 |
| Kyntra Bio | 221 open or running | phase 4since Aug 8, 2019 | Sep 25, 2008 | Sep 2030phase 3 · NCT07722988 |
| AstraZeneca | 30 open or running | phase 4since Dec 3, 2020 | Jun 24, 2014 | none ahead |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 33 studies since Sep 25, 2008.
- Nov 13, 2016Phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT02964936 · 100 enrolled · Japan
- Dec 8, 2016Phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT02988973 · 334 enrolled · Japan
- Aug 22, 2017Phase 3 study in AnemiaKyntra Bio · NCT03263091 · 184 enrolled · United States, Australia, Belgium and more
- Oct 2, 2017Phase 3 study in AnemiaKyntra Bio · NCT03303066 · 43 enrolled · China
- May 21, 2019Phase 1 study in Healthy Adult SubjectsAstellas Pharma · NCT03960489 · 24 enrolled · Germany
- Aug 8, 2019Phase 4 study in AnemiaKyntra Bio · NCT04059913 · 318 enrolled · China
- Aug 30, 2019Phase 2 study in AnemiaKyntra Bio · NCT04076943 · 92 enrolled · United States
- May 27, 2020Phase 3 study in Anemia Associated With End Stage Renal Disease (ESRD)Kyntra Bio · NCT04410198 · 203 enrolled · United States
- Jul 21, 2020Phase 3 study in Anemia Associated With End Stage Renal DiseaseKyntra Bio · NCT04484857 · 283 enrolled · United States
- Nov 3, 2020Phase 3 study in AnemiaKyntra Bio · NCT04621331 · United States
- Dec 3, 2020Phase 4 study in Renal Insufficiency, ChronicAstraZeneca · NCT04655027 · 25 enrolled · China
- Mar 19, 2022Phase 3 study in Chemotherapy Induced AnemiaKyntra Bio · NCT05301517 · 159 enrolled · China
- Jul 25, 2023Phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT05970172 · 98 enrolled · Belgium, Croatia, Denmark and more
- Jul 20, 2026Phase 3 study in Myelodysplastic SyndromesKyntra Bio · NCT07722988 · 201 planned
Ahead
- Oct 30, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicAstellas Pharma · NCT05970172
- Sep 2030Primary completion: phase 3 study in Myelodysplastic SyndromesKyntra Bio · NCT07722988
TargetBeta
“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 47 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07722988Myelodysplastic Syndromes | 3 | Not yet recruiting | Kyntra Bio | Sep 2030 | 201 |
| NCT05970172Renal Insufficiency, Chronic · Belgium, Croatia, Denmark and more | 3 | Active, not recruiting | Astellas Pharma | Oct 30, 2027 | 98 |
| NCT05301517Chemotherapy Induced Anemia · China | 3 | Completed | Kyntra Bio | Apr 3, 2023 | 159 |
| NCT04655027Renal Insufficiency, Chronic · China | 4 | Completed | AstraZeneca | Oct 12, 2021 | 25 |
| NCT04621331Anemia · United States | 3 | Withdrawn | Kyntra Bio | May 23, 2022 | 0 |
| NCT04484857Anemia Associated With End Stage Renal Disease · United States | 3 | Completed | Kyntra Bio | Jul 9, 2021 | 283 |
| NCT04410198Anemia Associated With End Stage Renal Disease (ESRD) · United States | 3 | Completed | Kyntra Bio | Jun 30, 2021 | 203 |
| NCT04076943Anemia · United States | 2 | Completed | Kyntra Bio | Mar 26, 2021 | 92 |
| NCT04059913Anemia · China | 4 | Completed | Kyntra Bio | Nov 19, 2021 | 318 |
| NCT03960489Healthy Adult Subjects · Germany | 1 | Completed | Astellas Pharma | Oct 14, 2019 | 24 |
| NCT03303066Anemia · China | 3 | Completed | Kyntra Bio | Jan 11, 2023 | 43 |
| NCT03263091Anemia · United States, Australia, Belgium and more | 3 | Terminated | Kyntra Bio | Mar 9, 2023 | 184 |
| NCT02988973Renal Insufficiency, Chronic · Japan | 3 | Completed | Astellas Pharma | Sep 13, 2019 | 334 |
| NCT02964936Renal Insufficiency, Chronic · Japan | 3 | Completed | Astellas Pharma | Aug 15, 2018 | 100 |
| NCT02965040Renal Insufficiency · Germany, United Kingdom | 1 | Completed | Astellas Pharma | Dec 4, 2017 | 34 |
| NCT02952092Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan | 3 | Completed | Astellas Pharma | Mar 13, 2018 | 303 |
| NCT02952040Healthy Subjects · Japan | 1 | Completed | Astellas Pharma | Dec 2016 | 18 |
| NCT02805374Healthy Subjects · Japan | 1 | Completed | Astellas Pharma | Aug 2016 | 16 |
| NCT02780726Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia · Japan | 3 | Completed | Astellas Pharma | Aug 2, 2017 | 56 |
| NCT02780141ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia · Japan | 3 | Completed | Astellas Pharma | Dec 12, 2017 | 75 |
| NCT02779764Hemodialysis Patients With Renal Anemia · Japan | 3 | Completed | Astellas Pharma | May 16, 2017 | 164 |
| NCT02693613Healthy Volunteers · Japan | 1 | Completed | Astellas Pharma | Apr 2016 | 34 |
| NCT02652819Anemia · China | 3 | Completed | Kyntra Bio | Jan 24, 2017 | 154 |
| NCT02652806Anemia · China | 3 | Completed | Kyntra Bio | Jan 24, 2017 | 305 |
| NCT02278341Anemia · Belgium, Bulgaria, Croatia and more | 3 | Completed | Astellas Pharma | Jun 8, 2017 | 838 |
| NCT02273726Anemia · United States, Puerto Rico | 3 | Completed | Kyntra Bio | Sep 19, 2018 | 741 |
| NCT02174731Anemia · United States, Australia, Bulgaria and more | 3 | Completed | AstraZeneca | Sep 26, 2018 | 2,133 |
| NCT02174627Anemia · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Oct 4, 2018 | 2,781 |
| NCT02252731Pharmacokinetics of FG-4592 · Germany | 1 | Completed | Astellas Pharma | Nov 2013 | 22 |
| NCT02161796PK for FG-4592 · Germany | 1 | Completed | Astellas Pharma | Dec 2013 | 48 |
| NCT02161224Hepatic Insufficiency · Bulgaria | 1 | Completed | Astellas Pharma | Dec 2013 | 16 |
| NCT02052310Anemia · United States, Argentina, Bulgaria and more | 3 | Completed | Kyntra Bio | Sep 21, 2018 | 1,043 |
| NCT02021318Renal Insufficiency, Chronic · Austria, Belarus, Bulgaria and more | 3 | Completed | Astellas Pharma | Mar 23, 2018 | 616 |
| NCT01964196Kidney Failure, Chronic · Japan | 2 | Completed | Astellas Pharma | Jul 6, 2015 | 107 |
| NCT01888445Kidney Failure, Chronic · Japan | 2 | Completed | Astellas Pharma | Sep 15, 2014 | 130 |
| NCT01887600Anemia · Belarus, Belgium, Bulgaria and more | 3 | Completed | Astellas Pharma | Nov 1, 2017 | 594 |
| NCT01750190Anemia · United States, Argentina, Australia and more | 3 | Completed | Kyntra Bio | Sep 24, 2018 | 922 |
| NCT01630889Renal Insufficiency, Chronic · United States, Puerto Rico | 2 | Completed | Kyntra Bio | Dec 12, 2019 | 15 |
| NCT01599507Anemia · China | 2 | Completed | Kyntra Bio | Jan 2013 | 91 |
| NCT01596855Anemia · China | 2 | Completed | Kyntra Bio | Jan 2013 | 96 |
| NCT01414075Anemia · United States, Hong Kong, Russian Federation and more | 2 | Completed | Kyntra Bio | Jan 10, 2013 | 60 |
| NCT01376063Healthy Adult Subjects | 1 | Completed | Kyntra Bio | May 2010 | 20 |
| NCT01244763Renal Insufficiency, Chronic · United States, Puerto Rico | 2 | Completed | Kyntra Bio | Jun 13, 2012 | 145 |
| NCT01147666Kidney Failure, Chronic · United States | 2 | Completed | Kyntra Bio | Oct 15, 2012 | 161 |
| NCT01083888Anemia · Japan | 1 | Completed | Astellas Pharma | Jun 7, 2010 | 12 |
| NCT00978198Healthy Volunteers · Japan | 1 | Completed | Astellas Pharma | Jun 2010 | 100 |
| NCT00761657Renal Insufficiency, Chronic · United States | 2 | Completed | Kyntra Bio | Jun 21, 2010 | 117 |
How it is read
Names in the registry
- “Roxadustat”, 25 entries
- “FG-4592”, 9 entries
- “roxadustat”, 8 entries
- “ASP1517”, 5 entries
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 7 studies
- Kidney Failure, Chronic, 4 studies
- Myelodysplastic Syndromes, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.